Abstract
Background Moderate-to-severe allergic rhinitis (AR) is often poorly controlled. Patients remain symptomatic on treatment, despite multiple therapies. A more effective treatment is needed. We assessed the efficacy of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) during different seasons and for different symptoms and severities vs AZE, FP or placebo (PLA).
Highlights
Moderate-to-severe allergic rhinitis (AR) is often poorly controlled
We assessed the efficacy of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) during different seasons and for different symptoms and severities vs AZE, FP or placebo (PLA)
Overall change from baseline (CFB) in reflective total nasal symptom score was the primary endpoint. It was assessed by severity post-hoc in 2 ways
Summary
A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity. Claus Bachert1*, Wytske Fokkens, Peter Hellings, Glenis Scadding, Ullrich Munzel, Joaquim Mullol. From The 10th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2015) Stockholm, Sweden. From The 10th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2015) Stockholm, Sweden. 19-21 February 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
